You are here

  • Home
  • Archive
  • Volume 77, Issue Suppl 2
  • FRI0398 Sl-401, a novel targeted therapy directed to the interleukin-3 receptor (CD123), kills plasmacytoid dendritic cells from systemic sclerosispatients

Alerts

Article menu

Download PDFPDF

FRIDAY, 15 JUNE 2018
Systemic sclerosis, myositis and related syndromes – etiology, pathogenesis and animal models
FRI0398 Sl-401, a novel targeted therapy directed to the interleukin-3 receptor (CD123), kills plasmacytoid dendritic cells from systemic sclerosispatients
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address